Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties ; volume:36 ; number:7 ; day:17 ; month:5 ; year:2019 ; pages:1700-1714 ; date:7.2019
Advances in therapy ; 36, Heft 7 (17.5.2019), 1700-1714, 7.2019
- Creator
-
Yun, Jihoon
Kim, Jihyun
Chung, Jihyun
Hwang, Su-Jeong
Park, Su Jin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-019-00973-y
- URN
-
urn:nbn:de:101:1-2019103100101758185077
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yun, Jihoon
- Kim, Jihyun
- Chung, Jihyun
- Hwang, Su-Jeong
- Park, Su Jin
- SpringerLink (Online service)
Other Objects (12)
Focused physicochemical stability study of reconstituted trastuzumab biosimilar SB3 (Ontruzant ®) stored in the original vials over 28 days
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to Pegfilgrastim
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Focused physicochemical stability study of reconstituted trastuzumab biosimilar SB3 (Ontruzant ®) stored in the original vials over 28 days
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to Pegfilgrastim
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Focused physicochemical stability study of reconstituted trastuzumab biosimilar SB3 (Ontruzant ®) stored in the original vials over 28 days
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar
Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
Demonstration of Physicochemical and Functional Similarity of Biosimilar Pegfilgrastim-cbqv to Pegfilgrastim
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations